All In Biotech

Drug Trial Radar · NCT07624513

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Oct 1, 2033

Study completion Mar 1, 2038

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; Bristol-Myers Squibb; Celgene Corporation; Regeneron Pharmaceuticals
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment. The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits. It is expected that about 720 participants will take part in this study.

Conditions

  • Multiple Myeloma

Interventions

  • IsatuximabDrug

    Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.

  • IberdomideDrug

    Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.

  • Bortezomib (B)Drug

    Commercial supply; used in induction and Arm G maintenance; administered subcutaneously in Arm G on Days 1 and 15 of each 28-day cycle.

  • DexamethasoneDrug

    Commercial supply; used in induction; may be administered intravenously or orally at investigator discretion; excluded from Arm G.

  • MelphalanDrug

    Commercial supply; used as conditioning therapy for Arm E before PBSC infusion/ASCT; administered intravenously.

  • LinvoseltamabDrug

    Supplied by Regeneron; used in Arm F consolidation for 8 cycles before maintenance therapy.

  • On Body Delivery System (OBDS)Device

    Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-Year Sustained Minimal Residual Disease (sMRD)-negative Complete Response (CR) Rate [Cohort 1] (Step 2)Time frame: Assessed after Step 2 maintenance cycle 36 (cycle duration=4 weeks), at 144 weeks/36 months.
  2. 1-Year MRD-Negative CR Rate [Cohort 2] (Step 2)Time frame: Assessed 1-year after Step 2 consolidation randomization.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts · Not yet recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.